Skip to main content

Table 3 Summery of DVH analysis for PTV, bladder and femurs

From: Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case

 

3D-PRE

3D-POST

RA-PRE

RA-POST

p

 

PTV Target

 

V95% [%]

99.8 ± 0.2

99.9 ± 0.1

 99.7 ± 0.2

99.7 ± 0.2

-

 

PTV Non Target

 

V95% [%]

93.7 ± 9.2

96.6 ± 4.9

86.5 ± 13.8

94.5 ± 7.5

a,b,d,f

 

Bladder

 

D2% [Gy]

48.5 ± 5.1

49.0 ± 5.2

47.4 ± 3.6

46.1 ± 4.2

-

Mean [Gy]

33.4 ± 8.5

30.1 ± 6.5

32.1 ± 5.7

30.6 ± 3.8

c

D30% [Gy]

25.9 ± 5.4

18.3 ± 5.7

18.7 ± 3.3

17.6 ± 2.1

a,b,c

V40Gy [%]

20.7 ± 12.5

14.9 ± 9.5

11.9 ± 10.1

8.1 ± 5.4

a,b,c,d,e,f

 

Right Femur

 

Mean [Gy]

32.0 ± 7.5

29.9 ± 6.6

19.7 ± 4.5

18.4 ± 1.9

b,c,d,e

D2% [Gy]

41.7 ± 5.6

42.7 ± 4.7

28.2 ± 7.4

28.1 ± 3.9

b,c,d,e

 

Left Femur

 

Mean [Gy]

31.9 ± 7.0

30.2 ± 6.7

18.5 ± 4.4

20.1 ± 4.7

b,c,d,e

D2% [Gy]

41.7 ± 5.4

42.5 ± 5.3

28.7 ± 7.3

28.0 ± 6.8

b,c,d,e

  1. The p < 0.05 for: a (3D-Pre vs 3D Post); b (3D-Pre vs RA-Pre); c (3D-Pre vs RA-Post); d (3D Post vs Ra-Pre); e (3D-Post vs RA-Post); f (RA-Pre vs RA-Post).